We confirm in this study the accuracy and precision of NGS workflow for simultaneous detection of CNVs and point mutations of BRCA1/2 genes, suggesting the use of this technological advancement in the diagnostic-therapeutic and care assessment of hereditary breast and ovarian cancer. The gene discussed is BRCA1; the disease is ovarian cancer.